COVID-19: Contracted by Fujifilm and Eli Lilly: Manufacture of drug substance for antibody drugs
-Aiming to spread to low- and middle-income countries-
FUJIFILM: FUJIFILM Diosynth Biotech (FDB)
Eli Lilly has been entrusted with the manufacture of drug substances for antibody drugs for the new coronavirus infection.
FUJIFILM Diosynth Biotech (FDB):
Production will begin in April 2021 at our Danish base.
Eli Lilly’s antibody drug for COVID-19 will contribute to the spread of antibody drugs to low- and middle-income countries.
FUJIFILM [Japan]
https://www.fujifilm.com/jp/ja/news/list/5537
FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody
for Low- and Middle-Income Countries
ILLERØD, Denmark,
October 8, 2020 —
FUJIFILM Diosynth Biotechnologies,
a world leading Contract Development and Manufacturing Organization (CDMO)
for biologics, viral vaccines and viral vectors,
today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP* facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator.
The commercial manufacturing falls under the agreement between Lilly and the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator,
to supply potential Lilly therapeutic antibodies for the prevention and treatment of COVID-19.
The Therapeutics Accelerator is an initiative launched by
- the Gates Foundation,
- Wellcome,
- Mastercard
to speed up the response to the COVID-19 pandemic by identifying, assessing, developing, and scaling up treatments
Fujifilm Global
https://www.fujifilm.com/news/n201009_02.html